Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 3,301–3,400 of 4,628
Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis
Lui, J. K., Bosch, N. A., Gillmeyer, K. R., & Reardon, C. C. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202002-0307rr · Cited by 2
Smallwood, N., & Goh, N. S. L. (2021) · doi:10.1093/med/9780198821328.003.0090 · Cited by 2
Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease
Tolle, L. B. (2022) · Case Reports in Pulmonology · doi:10.1155/2022/9942432 · Cited by 5
Pediatric pulmonology 2021 year in review: Rare and diffuse lung disease
Popler, J., Vece, T. J., Liptzin, D. R., & Gower, W. A. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.26227 · Cited by 2
Lee, J. H., Jang, J. H., Park, J. H., et al. (2023) · Medicine · doi:10.1097/md.0000000000032786 · Cited by 2
“[5] Previous major trials demonstrating the effect of anti-fibrotic drugs to contribute to food and drug administration approval have not reported data on the impact of treatment on cough.[6,7] Although some studies show efficacy”
BackgroundEpigenetics of the pathogenic myofibroblast in lung disease
Bernau, K., Sandbo, N. K., & Brasier, A. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-823931-5.00018-9 · Cited by 2
Enfermedad pulmonar intersticial en el lupus eritematoso sistémico: búsqueda avanzada
Santacruz, J. C., Mantilla, M. J., Rodríguez-Salas, G., et al. (2023) · Revista Colombiana de Reumatología · doi:10.1016/j.rcreu.2022.10.004 · Cited by 2
Ma, M., Cao, M., Gao, Y., Qiu, X., Jiang, H., & Cai, H. (2023) · Medicine · doi:10.1097/md.0000000000033722 · Cited by 2
Ballesteros, B. L.-M., López‐de‐Andrés, A., Jiménez‐García, R., Zamorano‐León, J. J., Carabantes-Alarcón, D., Cuadrado‐Corrales, N., del-Barrio, J. L., Pérez‐Farinós, N., & de Miguel‐Díez, J. (2023) · Healthcare · doi:10.3390/healthcare11111534 · Cited by 2
“[25] have shown less decline in lung function and improved survival, there continues to be an inexorable progression of the disease towards the development of respiratory failure, pulmonary hypertension, and death, so in advanced stages of the disease, the only treatment that has been shown to improve quality of life…”
BackgroundLes cryobiopsies pulmonaires transbronchiques dans les pneumopathies infiltrantes diffuses
Ménigoz, C., Dirou, S., Sagan, C., Corne, F., Moui, A., Defrance, C., Liberge, R., Morla, O., Patarin, V., Nicolas, A., et al. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.04.003 · Cited by 4
Anti-UBE2T antibody: A novel biomarker of progressive-fibrosing interstitial lung disease
Hikichi, M., Gon, Y., Ooki, T., Morisawa, T., Mizumura, K., Kozu, Y., Hiranuma, H., Nakagawa, Y., Shimizu, T., & Maruoka, S. (2023) · Respiratory Investigation · doi:10.1016/j.resinv.2023.05.006 · Cited by 2
Iwasaki, K., Wakabayashi, H., Saiki, A., Ueshiba, H., Murakami, Y., & Matsuzawa, Y. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00396-w · Cited by 4
Schweikert, A., Kenny, S., Oglesby, I. K., Glasgow, A. M. A., Santi, C. D., Gensch, I., Lachmann, N., Desroziers, T., Fletcher, C., Snijders, D., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03598-9 · Cited by 2
Childhood interstitial lung disease: When to suspect and what to do
Fenu, G., Astori, C., & Lombardi, E. (2023) · Global Pediatrics · doi:10.1016/j.gpeds.2023.100110 · Cited by 2
Mathur, T., & Singh, I. (2023) · Current Drug Research Reviews · doi:10.2174/0125899775269970231218100959 · Cited by 3
Francescato, R., Moretti, M., & Bersini, S. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10644 · Cited by 2
Le concept de pneumopathie interstitielle diffuse avec manifestations auto-immunes (IPAF)
Bermudez, J., Habert, P., & Coiffard, B. (2024) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2024.02.005 · Cited by 3
What causes cough in pulmonary fibrosis, and how should we treat it?
Myall, K. J., Cho, P. S. P., & Birring, S. S. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001087 · Cited by 2
Integrating the assessment of quality of life in care and research in pulmonary fibrosis
Aronson, K. I., Swigris, J. J., & Wijsenbeek, M. S. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001095 · Cited by 3
Furuta, K., Fujimoto, D., Matsunashi, A., Shibaki, R., Taniya, S., Tanaka, M., Shimada, Y., Nagata, K., Tomii, K., & Yamamoto, N. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107721 · Cited by 2
“Bubbly lung”, a honeycombing variant with more favorable outcome
Tzilas, V., Hartman, T. E., Charokopos, A., Decker, P. A., & Ryu, J. H. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.08.012 · Cited by 2
An Eternal Dilemma: Exposing the Impact of Immortal Time Bias on Antifibrotic Effectiveness
Kyle, A. R., & Dempsey, T. M. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202407-717ed · Cited by 2
Carlson, L., Kalafatis, D., Pesonen, I., Magnusson, J. M., & Sköld, M. C. (2024) · Chronic Respiratory Disease · doi:10.1177/14799731241299443 · Cited by 3
Fujiwara, M., Ikesue, H., Yamaoka, K., Uchida, M., Uesawa, Y., Muroi, N., & Shimizu, T. (2024) · In Vivo · doi:10.21873/invivo.13841 · Cited by 3
Diaz, C. M., Caballeria, E., & Torres, J. S. (2025) · Fibrosis · doi:10.70322/fibrosis.2025.10001 · Cited by 4
Gao, Z., Cao, S., Yuan, H., Wu, J. Z., & Zou, G. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114337 · Cited by 2
Cardillo, C., Criner, G. J., & Gayen, S. K. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666251326743 · Cited by 4
Genecand, L., Wacker, J., Guerreiro, I., Lechartier, B., Beghetti, M., Pohle, S., Darie, A. M., Lichtblau, M., Ulrich, S., Guler, S. A., et al. (2025) · Respiration · doi:10.1159/000544800 · Cited by 2
A Twist in the Fibrotic Tale: The Overlooked Vasculopathy in Idiopathic Pulmonary Fibrosis
Tonelli, A. R., & Sahay, S. (2025) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202502-0465ed · Cited by 2
Advances in management of pulmonary fibrosis
Lachowicz, J. A., Steinfort, D., Smallwood, N., & Prasad, J. D. (2025) · Internal Medicine Journal · doi:10.1111/imj.70051 · Cited by 3
Li, R., Cheng, S., Jia, Y., Wang, H., Chu-jie, L., Duan, W., Wang, X., Xiao, Q., & Liu, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113781 · Cited by 2
Wang, Y., Fan, W., Guo, Y., Sun, L., Hu, Y., Chen, J., Gong, L., & Xie, Z. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117768 · Cited by 2
Kondoh, Y., Ito, T., Kimura, H., Bao, H., & Kuwana, M. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03713-x · Cited by 6
Kaneko, T., Okuda, R., Takemura, T., Iwasawa, T., Haga, S., Takeda, Y., Hagiwara, E., & Ogura, T. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.06.004 · Cited by 3
Morrison, H. G., Dao, K., Holte, D., et al. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00065 · Cited by 2
Idiopathic Inflammatory Myositis (IIM) Related Interstitial Lung Disease (ILD): Treatment Options
Alrehaili, G. A., Farah, W. H., Tzilas, V., & Baqir, M. (2025) · Current Pulmonology Reports · doi:10.1007/s13665-025-00383-2 · Cited by 2
Sotiropoulou, V., Theochari, E., Katsaras, M., Tsiri, P., Komninos, D., Christopoulos, I., Tsirikos, G., Kalogeropoulou, C. P., Daoussis, D., Karkoulias, K., et al. (2025) · Medicina · doi:10.3390/medicina61091594 · Cited by 3
“…use of antifibrotic agents in AE-IPF, evidence indicates that both anti-fibrotics exert a rather preventive rather than therapeutic role considering that nintedanib may prolong the time to the first AE-IPF, while pirfenidone could lower the risk of respiratory-related hospital admissions [19–22].”
Ramosetron as a Supportive Agent to Continue Nintedanib in Patients with Interstitial Lung Disease
Satonaga, Y., Kudoh, R., Hata, M., Shigenaga, T., & Komiya, K. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5984-25 · Cited by 2
Effectiveness of antifibrotic treatment in real-world patients with progressive pulmonary fibrosis
Niitsu, T., Fukushima, K., Komukai, S., Yamamoto, R., Shiroyama, T., Nii, T., Takata, S., Hashimoto, K., Abe, Y., Hirata, H., et al. (2025) · Respiratory Medicine · doi:10.1016/j.rmed.2025.108347 · Cited by 3
Zhou, S., Dong, Y.-X., Tian, J., Che, G., & Lai, Y. (2025) · Regenerative Therapy · doi:10.1016/j.reth.2025.09.005 · Cited by 3
When Malignancies Mimic Interstitial Lung Disease: A Case Series and Review of the Literature
Guler, S. A., & Berezowska, S. (2015) · Journal of Clinical Respiratory Diseases and Care · doi:10.4172/2472-1247.1000104 · Cited by 2
Microencapsulation of Lefty-secreting engineered cells for pulmonary fibrosis therapy in mice
Ma, H., Qiao, S., Wang, Z., Geng, S., Zhao, Y., Hou, X., Tian, W., Chen, D., & Yao, L. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00295.2016 · Cited by 2
Palliative and end of life care in idiopathic pulmonary fibrosis
Newell, K. A., Smith, K., & Russell, A. (2018) · Primary Health Care · doi:10.7748/phc.2018.e1387 · Cited by 2
The cardiovascular system in idiopathic pulmonary fibrosis
Chong, S. G., Yanagihara, T., & Kolb, M. R. J. (2020) · European Respiratory Society eBooks · doi:10.1183/2312508x.10028319 · Cited by 2
Self-citationAzuma, A., & Richeldi, L. (2020) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2020.0005 · Cited by 2
Self-citationPhase three clinical trials in idiopathic pulmonary fibrosis
Sgalla, G., Lerede, M., & Richeldi, L. (2021) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2021.1882299 · Cited by 2
Self-citationAntifibrotic Drugs for COVID-19: From Orphan Drugs to Blockbusters?
Corrie, L., Muzaffar-Ur-Rehman, M., Kukatil, L., Devasari, M., & Shirisha, A. (2021) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x17666210304100043 · Cited by 2
Clinical Trials for Idiopathic Pulmonary Fibrosis and the Role of Health Systems
Farrand, E. D., & LIMPER, A. H. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.03.006 · Cited by 2
Anderson, M. R., Aronson, K. I., Diamond, J. M., Christie, J. D., & Singer, J. P. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202201-019rl · Cited by 2
Trial of a Phosphodiesterase 4 Inhibitor for Idiopathic Pulmonary Fibrosis. Reply.
Richeldi, L., Stowasser, S., & Maher, T. M. (2022) · PubMed · doi:10.1056/nejmc2209529 · Cited by 2
Self-citationArai, N., Nakajima, M., Matsuyama, M., et al. (2023) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0054le · Cited by 2
Holland, A. E., & Swigris, J. J. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_16 · Cited by 2
Pirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis
Miura, Y., & Azuma, A. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1029453 · Cited by 2
Self-citationBitterman, P. B. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201411-529mg · Cited by 2
Elements: in this month’s issue
Donnelly, S. C. (2015) · QJM · doi:10.1093/qjmed/hcv147 · Cited by 2
Wollin, L. (2015) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2015.05.007 · Cited by 2
European IPF Patient Charter: an SOS to the world
Crestani, B. (2016) · European Respiratory Journal · doi:10.1183/13993003.01902-2015 · Cited by 2
Pruebas de función pulmonar en la fibrosis pulmonar idiopática: ¿más allá de la espirometría?
Casán, P., González, C. M., & Ancochea, J. (2016) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2016.02.017 · Cited by 3
Audibert, C., Livoti, C., & Cazé, A. (2016) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2016.04.008 · Cited by 2
Handa, T., & Azuma, A. (2015) · Springer eBooks · doi:10.1007/978-4-431-55582-7_9 · Cited by 2
Self-citationOccurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report
Cerri, S., Sgalla, G., Richeldi, L., et al. (2016) · Journal of Medical Case Reports · doi:10.1186/s13256-016-0916-5 · Cited by 2
Self-citationSafety management of treatment with nintedanib in clinical practice of IPF
Azuma, A. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.12.001 · Cited by 2
Self-citationPalliative and End-of-Life Care in Idiopathic Pulmonary Fibrosis
Lindell, K. O. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48024-6.00008-2 · Cited by 3
Pneumopathies interstitielles diffuses au cours de la polyarthrite rhumatoïde
Juge, P., & Dieudé, P. (2017) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2017.08.002 · Cited by 2
Rees, C. J., Pollack, C. V., & Riese, V. G. (2019) · Springer eBooks · doi:10.1007/978-3-319-63895-9_40 · Cited by 2
Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis
Pasciuto, G., Inchingolo, R., Condoluci, C., Magnini, D., Iovene, B., & Richeldi, L. (2018) · Current Pulmonology Reports · doi:10.1007/s13665-018-0209-0 · Cited by 2
Self-citationCarrera, L. G., & Walther, R. Á.-S. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.06.002 · Cited by 2
ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine
Michaud, G. C., Channick, C. L., Marion, C. R., Tighe, R. M., Town, J. A., Luks, A. M., Richards, J. B., Kher, S., Mota, P., Hong, G., et al. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201504-194cme · Cited by 2
Novel drug targets in idiopathic pulmonary fibrosis
Calvello, M., Flore, M. C., & Richeldi, L. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1590196 · Cited by 2
“Even if no significant effects on overall mortality were demonstrated, a reduction of FVC decline, consistent with a slower disease progression, was shown [13].”
BackgroundSelf-citationInterstitial Lung Disease and ANCA-Associated Vasculitis
Flores-Suárez, L. F., & Sacoto, G. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00127-9 · Cited by 2
Dhar, R. (2019) · Lung India · doi:10.4103/lungindia.lungindia_379_19 · Cited by 2
Tratamiento farmacológico en la fibrosis pulmonar idiopática. Drogas modificadoras de enfermedad
FLORENZANO, M., V, & C, F. R. (2019) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482019000400287 · Cited by 3
Molecular approach to the classification of chronic fibrosing lung disease—there and back again
Verleden, S. E., Braubach, P., Kühnel, M., Dickgreber, N. J., Brouwer, E., Tittmann, P., Laenger, F., & Jonigk, D. D. (2020) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-02964-9 · Cited by 2
“Nintedanib, approved in 2014, also slows down the FVC decline [10].”
BackgroundYazaki, K., Nonaka, M., Shigemasa, R., et al. (2021) · Radiology Case Reports · doi:10.1016/j.radcr.2021.02.019 · Cited by 2
“On the other hand, in the INPLUSIS study, no significant difference was found in the effect of nintedanib on IPF patients with or without honeycombing on CT [6] .”
BackgroundAntifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?
Soskis, A., & Hallowell, R. W. (2021) · Respiration · doi:10.1159/000515607 · Cited by 2
Brugière, O., & Verleden, S. E. (2021) · European Respiratory Journal · doi:10.1183/13993003.04607-2020 · Cited by 2
Idiopathic pulmonary fibrosis. Can we always diagnose and treat it right?
Vašáková, M. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.151 · Cited by 2
Sakamoto, N., Hamada, N., Okamoto, M., Tobino, K., Ichiyasu, H., Ishii, H., Ichikado, K., Morimoto, S., Hosogaya, N., & Mukae, H. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047249 · Cited by 3
Wilson, A. M., Clark, A., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Hammond, M., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., et al. (2021) · Efficacy and Mechanism Evaluation · doi:10.3310/eme08090 · Cited by 3
Pulmonary Fibrosis Progression Prediction Using Image Processing and Machine Learning
Abo-eleneen, A., Patel, M. K., & Al-Maadeed, S. A. (2021) · Advances in Science, Technology & Innovation/Advances in science, technology & innovation · doi:10.1007/978-3-030-14647-4_11 · Cited by 2
Palliative Care in Interstitial Lung Disease
Wijsenbeek, M. S., & Moor, C. C. (2021) · Respiratory medicine · doi:10.1007/978-3-030-81788-6_11 · Cited by 2
Palliative Care in Lung Disease
FERRELL, B. R., & Harrington, A. (2021) · Respiratory medicine · doi:10.1007/978-3-030-81788-6_1 · Cited by 2
Corticosteroid Resistant Pulmonary Fibrosis: Pathophysiology and Management
Alghamdi, D., Kawy, H. S. A., & Damanhouri, Z. A. (2021) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2021/v33i47a33042 · Cited by 3
Niel, C., Ricordel, C., Guy, T., Kerjouan, M., Latour, B. R. D., Chiforeanu, D., Léderlin, M., & Jouneau, S. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-03177-7 · Cited by 2
Review of the British Thoracic Society Winter Meeting 2014, 3-5 December, London, UK
Greening, N. J., José, R. J. P., Chalmers, J. D., & Janes, S. M. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-206784 · Cited by 1
Rezaee, R., & Hosseinzadeh, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00131-6 · Cited by 2
Cottin, V., & Valenzuela, C. (2016) · European Respiratory Society eBooks · doi:10.1183/2312508x.10006115 · Cited by 3
Self-citationDevelopments in the management of idiopathic pulmonary fibrosis
(2015) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2015.7.0337 · Cited by 2
From the Gut to the Lung: Evidence of Antifibrotic Activity of Endocrine Fibroblast Growth Factor 19
Guzy, R., Bollenbecker, S., & Krick, S. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0057ed
Majewski, S., Królikowska, M., Costabel, U., Piotrowski, W. J., & Ochman, M. (2022) · Case Reports in Pulmonology · doi:10.1155/2022/4054339 · Cited by 2
Self-citationGórska, K., Maskey‐Warzęchowska, M., Barnaś, M., Białas, A. J., Barczyk, A., Jagielska-Len, H., Jassem, E., Kania, A., Lewandowska, K. B., Majewski, S., et al. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221117982 · Cited by 2
Brunswicker, A., Tan, M. Z. Y., Garner, M., & Rammohan, K. S. (2022) · Shanghai Chest · doi:10.21037/shc-22-28 · Cited by 2
Matson, S. M., Lee, J. S., & Fontenot, A. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00072-1 · Cited by 2
Lederer, C., Buschulte, K., Hellmich, B., Heußel, C. P., Kriegsmann, M., Polke, M., & Kreuter, M. (2023) · Zeitschrift für Pneumologie · doi:10.1007/s10405-023-00514-z · Cited by 3
Capaccione, K. M., & Salvatore, M. M. (2023) · Clinical Imaging · doi:10.1016/j.clinimag.2023.07.002 · Cited by 2
Inhaled nintentanib, Pirfenidone and Macitentan for Pulmonary Fibrosis: a Laboratory Experiment
Zarogoulidis, P., Petridis, D., Huang, H., Bai, C., Oikonomou, P., Nikolaou, C., Matthaios, D., Perdikouri, Ε.-I., Papadopoulos, V., Petanidis, S., et al. (2023) · Therapeutic Delivery · doi:10.4155/tde-2023-0045 · Cited by 2
John, A., Sherigar, P., Hegde, V., George, V. T., Kudva, A., & Gadicherla, S. (2023) · Journal of Prosthetic Dentistry · doi:10.1016/j.prosdent.2023.07.014 · Cited by 5
Assessing the Burden and Prognostic Value of Cough in Idiopathic Pulmonary Fibrosis
Johnston, J., & Rivera‐Ortega, P. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202305-483ed · Cited by 2
Nintedanib-Induced Colitis Can Mimic Inflammatory Bowel Disease
Odah, T., Karime, C., Hashash, J. G., & Farraye, F. A. (2024) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001282 · Cited by 4
Suissa, S., & Ernst, P. (2015) · European Respiratory Journal · doi:10.1183/13993003.01274-2015 · Cited by 2
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.